Company: HURA
Filing Date: 2025-08-12
Form Type: S-1
Source: 0001193125-25-179009
Chunk: 303

Company: TuHURA Biosciences, Inc./NV
Filing Date: 2025-08-12
Form: S-1
Chunk 303
---
                            |     |                          2023$ |     |     | 2022$ |     |     |                        2023$ |     |     | 2022$ |     |
| Research and development   |     |                                |  24 |     |       | 134 |     |                              |  93 |     |       | 274 |
| General and administrative |     |                                | 141 |     |       | 302 |     |                              | 232 |     |       | 680 |
|                            |     |                                | 165 |     |       | 436 |     |                              | 325 |     |       | 954 |

All of the stock option expense for the periods ended December 31, 2023, and 2022, has been recognized as additional paid in capital. The aggregate intrinsic value of stock options outstanding as well as stock options exercisable was nil as of December 31, 2023, and 2022, respectively. As of December 31, 2023, there was $ 603 in unrecognized compensation expense that will be recognized over the next 2.36 years.

The following table sets forth changes in unvested stock options under all plans:

| Unvested at June 30, 2023     |     | Number ofOptions(in thousands) | 118 |   |     | Weightedaverageexerciseprice$ | 24.12 |
|:------------------------------|:----|:-------------------------------|----:|:--|:----|:------------------------------|------:|
| Granted                       |     |                                |  89 |   |     |                               |  4.66 |
| Vested                        |     |                                | (40 | ) |     |                               | 19.68 |
| Forfeited                     |     |                                | (31 | ) |     |                               |  8.26 |
| Unvested at December 31, 2023 |     |                                | 136 |   |     |                               | 16.33 |

The aggregate intrinsic value of unvested stock options at December 31, 2023, was nil (2022 - nil ). The unvested stock options have a remaining weighted average contractual term of 9.00 years (2022 - 9.18 ).

<div align='center'>F-6 3</div>

Kintara Therapeutics, Inc. Notes to Condensed Consolidated Interim Financial Statements (